<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=1400074&amp;fmt=gif">

Nodify CDT Test

Help identify patients with likely malignant lung nodules

Nodify CDT™ testing supports clinical decision-making so physicians can more confidently identify patients with lung nodules who have a higher risk of malignancy and may benefit from timely intervention.

What does the Nodify CDT test measure?

Nodify CDT testing helps decipher if a lung nodule is likely malignant, instilling confidence in the recommended path forward for both physicians and patients.

Order Nodify CDT

Which patients are right for Nodify CDT?

Nodify CDT is intended for patients with incidental lung nodules:

Clinically Validated Results

  • The Nodify CDT test measures autoantibodies to tumor-associated antigens to help physicians detect lung cancer across histologies and stages.1,2
  • In the clinical validation study3, Nodify CDT demonstrated a test performance of 98% specificity with a 78% positive predictive value (PPV) for the High Level test result.


Financial Assistance

We understand the financial stresses that health issues can place on patients. We have created a financial assistance program for patient with financial responsibility to assist in providing affordable care.

To learn more about our financial assistance program, please contact our Customer Care team at 1.866.432.5930.

Contact Us

Interested in ordering a Nodify LungTM test kit?

The Nodify Lung Blood Specimen Collection Kit is used for both the Nodify CDT™ and the Nodify XL2™ proteomic tests.


Get in touch

Contact Us

Data Library

Discover More
  1. Jett J, Healey G, Macdonald I, et al. “Determination of the detection lead time for autoantibody biomarkers in early stage lung cancer using the UKCTOCS cohort.” Journal of Thoracic Oncology. 2017; 12(11): S2170.
  2. Chapman C, Healey G, Murray A, et al. “EarlyCDT—Lung test: improved clinical utility through additional autoantibody assays.” Tumor Biology. 2012; 33(5):1319–1326.
  3. Healey et al ”Tumor-Associated Autoantibodies: Re-Optimization of EarlyCDT-Lung Diagnostic Performance and Its Application to Indeterminate Pulmonary Nodules” Journal of Cancer Therapy. 2017. 8, 506-517.